Biomarin Pharmaceutical (BMRN) Operating Income Growth (1y) (2010 - 2026)
Biomarin Pharmaceutical (BMRN) Operating Income Growth (1y) (2010 - 2026) Analysis & Trends
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Op. Inc Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -24.89% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 2,150.96% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 80.62% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 8.65% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 145.20% |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | Biomarin Pharmaceutical | 11.65 Bn | 9.42 Bn | 571.21 Mn | -42.10% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -42.10% |
| Dec 31, 2025 | -127.64% |
| Sep 30, 2025 | -141.00% |
| Jun 30, 2025 | 129.87% |
| Mar 31, 2025 | 153.10% |
| Dec 31, 2024 | 491.69% |
| Sep 30, 2024 | 273.11% |
| Jun 30, 2024 | 83.71% |
| Mar 31, 2024 | 41.76% |
| Dec 31, 2023 | 308.43% |
| Sep 30, 2023 | 1,362.93% |
| Jun 30, 2023 | 67.47% |
| Mar 31, 2023 | -54.56% |
| Dec 31, 2022 | 80.13% |
| Sep 30, 2022 | 95.46% |
| Jun 30, 2022 | 235.44% |
| Mar 31, 2022 | 447.42% |
| Dec 31, 2021 | -27.89% |
| Sep 30, 2021 | 4.87% |
| Jun 30, 2021 | 128.51% |